A Personalized 14-3-3 Disease-Targeting Workflow Yields Repositioning Drug Candidates
Open Access
Abstract
Rare diseases typically evade the application of the standard drug discovery and development pipelines due to their understudied molecular etiology and the small market size. Herein, we report a rare disease-directed workflow that rapidly studies the molecular features of the disorder, establishes a high-throughput screening (HTS) platform, and conducts an HTS of thousands of approved drugs to identify and validate repositioning drug candidates. This study examines the pediatric neurological disorder caused by de novo mutations in YWHAG, the gene encoding the scaffolding protein 14-3-3γ, and the workflow discovers nuclear relocalization and a severe drop in 14-3-3γ binding to its phosphorylated protein partners as the key molecular features of the pathogenic hotspot YWHAG mutations. We further established a robust in vitro HTS platform and screened ca. 3000 approved drugs to identify the repositioning drug candidates that restore the deficient 14-3-3γ-phosphotarget interactions. Our workflow can be applied to other 14-3-3-related disorders and upscaled for many other rare diseases.Keywords
All Related Versions
Funding Information
- fondation privee des hug
- Aga Khan Foundation
- Fondation de l’Hôpital de La Tour
This publication has 77 references indexed in Scilit:
- Clinical and Molecular Profiling in GNAO1 Permits Phenotype–Genotype CorrelationMovement Disorders, 2024
- A novel variant in YWHAG further supports phenotype of developmental and epileptic encephalopathyAmerican Journal of Medical Genetics Part A, 2021
- The 14‐3‐3/SLP76 protein–protein interaction in T‐cell receptor signalling: a structural and biophysical characterizationFEBS Letters, 2020
- Complex molecular regulation of tyrosine hydroxylaseJournal of Neural Transmission, 2014
- Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis‐Related DisordersMedicinal Research Reviews, 2014
- αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinomaHepatology, 2013
- A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic studyAnalytical and Bioanalytical Chemistry, 2008
- Comprehensive analysis ofLRRK2in publicly available Parkinson's disease cases and neurologically normal controlsHuman Mutation, 2008
- Expression of Concern: Mechanisms of synthetic serine protease inhibitor (FUT‐175)‐mediated cell deathCancer, 2007
- 14-3-3 proteins in neuronal development and functionMolecular Neurobiology, 1998